Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548964 · ClinicalTrials.gov registry record · Phase 1
Continuation Ketamine in Major Depression
A Phase 1 study, sponsored by James Murrough.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00548964 is a Phase 1 study that has completed, run by James Murrough. The registered enrollment target is 36 participants.
The verdict
NCT00548964, a Phase 1 study, has completed, sponsored by James Murrough.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial series of ketamine infusions. Ketamine is a Food and Drug Administration approved anesthetic (a drug used to produce loss of consciousness before and during surgery). Ketamine is not approved for the treatment of major depressive disorder and is considered experimental in this study.
Interventions
- DRUG Ketamine
- DRUG Lithium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548964
The ClinicalTrials.gov registry entry for NCT00548964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Murrough, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT00548964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548964 about?
NCT00548964 is a clinical study titled "Continuation Ketamine in Major Depression". As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial series of ke...
What is the current status of trial NCT00548964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-10. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00548964?
The interventions under investigation include: Ketamine (DRUG), Lithium (DRUG).
Who is sponsoring clinical trial NCT00548964?
This trial is sponsored by James Murrough, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.